Nitric ester derivatives and their use in treating gastrointestinal tumors
AssigneeNicox S.A.
InventorsPiero Del Soldato, Francesco Sannicolo
Life of this patent
Estimating the term…
Abstract
Use of the following groups of compounds or their compositions for the preparation of medicaments for the treatment of gastrointestinal tumors, such compounds having general formula: A-X1—NO2 or their salts, where A=R(COX)t and where t is an integer 0 or 1; X═O, NH, NR1c, where R1c is a linear or branched alkyl having from 1 to 10 C atoms; R is (IA) where t=1 and X1 is equal to —YO— where Y is a C1-C20 alkylene, C5-C7 cycloalkyl or oxyalkyl derivatives.
Claims6
A method for treatment of gastrointestinal tumors by administering compounds, having the formula:
- A-X1—NO2
- or their salts, where:
- A=R(COX)t wherein t is an integer 0 or 1;
- X═O, NH, NR1C wherein R1C is a linear or branched alkyl having from 1 to 10 C atoms;
- R is chosen from the following groups:
- Group I A), where t=1,
- 22
- where:
- RII5 is H, a linear C1-C3 alkyl, or a branched C1-C3 alkyl;
- RII6 has the same structure as RII5,
- RII1, RII2 and RII3 are each hydrogen, linear C1-C6 alkyl, branched C1-C6 alkyl, C1-C6 alkoxy, Cl, F, or Br;
- RII4 has the same structure as RII1, or is bromine;
- Group 11 A) chosen from the following:
- where, when t=1, R is
- 23
- where R2a and R3a are H, a linear C1-C12 alkyl, a branched C1-C12 alkyl, or allyl, with the proviso that when one of the two is allyl the other is H;
- R1a is chosen from the subgroup II Aa) consisting of
- 24 25
- wherein:
- in the residue of formula (IV):
- RIII1 is H or SRIII3 where RIII3 contains from 1 to 4 linear or branched C atoms;
- and
- RIII2 is H or hydroxy;
- in the residue of formula (XXI):
- Rxxio is H, a linear alkyl having 1-6 carbon atoms, a branched alkyl having from 1 to 6 carbon atoms, a C1-C6 alkoxy-carbonyl bound to a C1-C6 carboxyalkyl, or a C1-C6 alkanoyl, optionally substituted with halogen, benzyl or halobenzyl, benzoyl or halobenzoyl;
- Rxxi is H, halogen, hydroxy, CN, a C1-C6 alkyl optionally containing OH groups, a C1-C6 alkoxy, acetyl, benzyloxy, SRxxi2 where Rxxi2 is a C1-C6 alkyl;
- a perfluoroalkyl having a 1-3 C atoms, a C1-C6 carboxyalkyl optionally containing OH groups, NO2, sulphamoyl, dialkyl sulphamoyl with the alkyl having from 1 to 6 C atoms, or difluoroalkylsulphonyl with the alkyl having from 1 to 3 C atoms;
- Rxxi1 is halogen, CN, a C1-C6 alkyl optionally containing one or more OH groups, a C1-C6 alkoxy, acetyl, acetamido, or benzyloxy, SRIII3 is as above defined, a perfluoroalkyl having from 1 to 3 C atoms, hydroxy, a carboxyalkyl having from 1 to 6 C atoms, hydroxy, a carboxyalkyl having from 1 to 6 C atoms, NO2, amino, mono- or dialkylamino having from 1 to 6 C atoms, sulphamoyl, a dialkyl sulphamoyl having from 1 to 6 C atoms, difluoroalkylsulphamoyl;
- or Rxxi together with Rxxi1 is an alkylene dioxy having from 1 to 6 C atoms;
- In the residue of formula (XXXV):
- Ar is phenyl, hydroxyphenyl optionally mono- or polysubstituted with halogen, an alkanoyl or alkoxy having from 1 to 6 C atoms, a trialalkyl having from 1-6 C atoms, cyclopentyl o-hexyl o-heptyl, thienyl, furyl, furyl containing OH, or pyridyl;
- Subgroup II Ab) consisting of:
- 26
- wherein:
- when IIIa) contains —CH(CH3)—COOH it is known as pranoprofen:
- α-methyl-5H-(1) benzopyran (2,3-b) pyridine-7-acetic acid;
- when residue (XXX) contains —CH(CH3)—COOH it is known as bermoprofen:
- dibenz(b,f)oxepin-2-acetic acid;
- residue (XXXI) is known as CS-670:
- 2-(4-2(2-oxo-1-cyclohexylidenemethyl)phenyl)propionic acid, when the radical is —CH(CH3)—COOH;
- when residue (XXXII) contains group —CH2COOH it is known as pemedolac;
- when residue (XXXIII) is saturated with —CH2COOH it is known as pyrazolac:
- 4-(4-chlorophenyl)-1-(4-fluorophenyl) 3-pyrazolyl acid derivatives;
- when residue (XXXVI) is saturated with —CH(CH3)—COO— it is known as zaltoprofen;
- when residue (XXXVII) is CH2—COOH it derives from the known mofezolac:
- 3,4-di p-methoxyphenyl)isoxazol-5-acetic acid;
- Group IIIA), where t=1,
- 27
- wherein:
- at least one of RIvd and RIvd1 is H and the other a linear or branched C1-C6 alkyl, or difluoroalkyl with the alkyl having from 1-6 C atoms, or RIvd and RIvd jointly form a methylene group;
- RIV has the following structure:
- 28
- where:
- in the residue of formula (II)):
- RIV-II is selected from the group consisting of an alkyl having from 1 to 6 C atoms, a cycloalkyl having from 3 to 7 C atoms, an alkoxymethyl having from 1 to 7 C atoms, a trifluoroalkyl having from 1 to 3 C atoms, vinyl, ethynyl, halogen, an alkoxy having from 1 to 6 C atoms, a difluroalkoxy with the alkyl having from 1 to 7 C atoms, an alkoxymethyloxy having from 1 to 7 C atoms, an alkylthiomethyloxy with the alkyl having from 1 to 7 C atoms, an alkylmethylthio with the alkyl having from 1 to 7 C atoms, cyano, difluoromethylthio, a substituted phenyl-, and phenylalkyl with the alkyl having from 1 to 8 C atoms;
- RIV-II, is a C2-C5 alkyl, a C2 or C3 alkyloxy, allyloxy, phenoxy, phenylthio, a cycloalkyl having from 5 to 7 C atoms, optionally substituted at position 1 by a C1-C2 alkyl;
- Group IV A)
- 29
- where A=RCOO, t=1,
- Group V A) chosen from the following:
- Subgroup V Aa) residues chosen from the following, where t=1
- 30
- subgroup V Ab), residue, where t=1:
- 31
- subgroup V Ac), residue, where t=0 and R is as follows:
- 32
- Subgroup V Ad) residues, where t=1 and R is as follows:
- 33
- subgroup Ae) resides, where t=1 and R is as follows:
- 34 35
- wherein:
- in compounds (V Ac1) Rvac1 attached to the oxygen atom in position 2 of the benzene ring of the N-(4-nitro-phenyl)methansulphonamide can be phenyl or cyclohexane, when Rvac1 is phenyl the residue is that of nimesulfide;
- in compounds (V Ac2) the residue of 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-bezopyran-4-one has been shown;
- in compounds (V Ac3) the atom X4 that links the radical 2,4-difluorothiophenyl to position 6 of the indanone ring of the residue 5-methanesulfonamido-1-indanone can be sulfur or oxygen;
- Group VIA), where t=1,
- 36
- where:
- R1 is group OCOR3;
- where R3 is methyl, ethyl or a linear or branched C3-C5 alkyl, or the residue of a single-ring heterocycle having 5 or 6 atoms which can be aromatic, partially or totally hydrogenated, containing one or more heteratoms independently chosen from O, N and S;
- R2 is hydrogen, hydroxy, halogen, a linear or whenever possible branched alkyl having from 1 to 4 C atoms, a linear or whenever possible branched alcoxyl having from 1 to 4 C atoms;
- a linear or whenever possible branched perfluoroalkyl having from 1 to 4 C atoms, for example trifluoromethyl, nitro, amino, mono- or di(C1-4)alkylamino;
- R1 and R2 jointly are the dioxymethylene group, with the proviso that when X═NH, then X1 is ethylene and R2═H;
- R1 cannot be OCOR3 at position 2 when R3 is methyl;
- nI being an integer from 0 to 1;
- X1 in formula A-X1—NO2 is a bivalent connecting bridge chosen from the following:
- YO where Y is a linear or branched C1-C20 alkylene, or an optionally substituted cycloalkylene having from 5 to 7 carbon atoms;
- 37
- where n3 is an integer from 0 to 3;
- 38
- where nf′ is an integer from 1 to 6;
- 39
- where R11═H or CH3 and nf is an integer from 1 to 6.
Use of compounds from groups IA) to VIA) for the treatment of gastrointestinal tumors.
Dependencies are inferred from the claim text.